Allscripts (MDRX) Announces New Share Buyback up to $300M

Allscripts Healthcare Solutions (NASDAQ MDRX) announced today that its Board of Directors has approved a new share repurchase program under which Allscripts may purchase up to $300 million of its common stock through December 31, 2021.

The new share repurchase program replaces the previously existing share repurchase program, which authorized Allscripts to repurchase $250 million of its common share through December 31, 2020. Allscripts has repurchased the entire amount available under the prior program.

"Extending and expanding Allscripts share repurchase program represents an attractive component of our capital deployment strategy," said Rick Poulton, Allscripts President and Chief Financial Officer.

Allscripts plans to repurchase shares from time to time in the open market, through transactions that may be characterized as derivatives (including accelerated share repurchases), or in privately negotiated transactions, subject to market conditions. There is no guarantee as to the exact number of shares or value that will be repurchased under the stock repurchase program, and Allscripts may discontinue purchases at any time. Whether Allscripts makes any repurchases will depend on many factors, including but not limited to its business and financial performance, the business and market conditions at the time, including the price of Allscripts shares, and other factors that management considers relevant.

You May Also Be Interested In

• ANI Pharmaceuticals to appeal Delaware court rulings in CG Oncology case
• Light & Wonder to report Q2 results Aug. 4, reaffirms FY26 outlook
• Couche-Tard renews buyback program for up to 74.2M shares